To explore the utility of Prostate Health Index (PHI) density for the detection of clinically significant prostate cancer (PCa) in a contemporary cohort of men presenting for diagnostic evaluation of PCa.
Objectives
To explore the utility of Prostate Health Index (PHI) density for the detection of clinically significant prostate cancer (PCa) in a contemporary cohort of men presenting for diagnostic evaluation of PCa.
Patients and Methods
The study cohort included patients with elevated prostatespecific antigen (PSA; >2 ng/mL) and negative digital rectal examination who underwent PHI testing and prostate biopsy at our institution in 2015. Serum markers were prospectively measured per standard clinical pathway. PHI was calculated as ([{À2}proPSA/free PSA] 9 [PSA] ½ ), and density calculations were performed using prostate volume as determined by transrectal ultrasonography. Logistic regression was used to assess the ability of serum markers to predict clinically significant PCa, defined as any Gleason score ≥7 cancer or Gleason score 6 cancer in >2 cores or >50% of any positive core.
Introduction
The use of serum prostate-specific antigen (PSA) for prostate cancer (PCa) screening has been the subject of extensive debate. Evidence from the European Randomized study of Screening for Prostate Cancer showed that PSA-based screening was associated with decreased PCa-specific mortality over long-term follow-up [1] . Nonetheless, these data also indicate that~781 men must be invited for screening and 27 men diagnosed with PCa in order to avoid a single death from the disease. Indeed, owing to the low specificity of PSA for cancer, PSA-based screening is associated with a high rate of negative biopsies and frequent overdetection of clinically insignificant disease [2, 3] . Given the limitations of PSA as a diagnostic marker, identifying accurate and reliable tools for PCa detection has remained a critical aim.
Aiming to improve on the diagnostic accuracy of PSA, several groups have explored the utility of PSA derivatives, such as PSA density (PSAD) and PSA velocity [4] . While limited as a diagnostic tool [5] , PSAD has been shown to have superior prognostic ability to PSA and has been adopted as a tool for guiding management in some settings [6, 7] . In addition, several new serum and urine biomarkers have been presented for clinical use, with varying results [8] . Among these is the Prostate Health Index (PHI), which combines serum PSA, free PSA (fPSA), and [À2]proPSA (p2PSA) in a mathematical formula [9] . PHI has demonstrated improved performance characteristics to PSA [10, 11] and has been approved by the US Food and Drug Administration for use in men with a normal DRE and elevated PSA level. We hypothesized that, similar to PSAD, PHI density could further improve on the discriminative ability of PHI. As such, we sought to evaluate the performance of PHI density in the diagnosis of PCa in a contemporary clinical setting.
Patients and Methods

Study Population
The present study cohort consisted of patients who underwent PHI testing at our institution as part of a diagnostic evaluation for PCa between December 2014 and December 2015 [12] and underwent prostate biopsy. Men with abnormal DRE were excluded because biopsy is generally performed in such patients regardless of their serum biomarker values. Baseline demographic and clinical data included age, African-American race, and serum PSA level. The Beckman Coulter Access â 2 immunoassay analyser (Beckman Coulter, Brea, CA, USA) was used to measure serum PSA, fPSA and p2PSA. PHI was calculated as ([p2PSA/fPSA] 9 [PSA] ½ ), and %fPSA was defined as ([fPSA/PSA] 9 100). Density calculations (PSAD and PHI density) were performed using prostate volume as determined on TRUS (using the standard ellipsoid formula) in all except one patient, for whom multiparametric MRI (mpMRI)-derived volume was used. Because both %fPSA and prostate volume are negatively associated with PCa [13, 14] , the measures were combined as a product (denoted as %fPSA 9 volume) and calculated as ([%fPSA/100] 9 [prostate volume in mL]).
The study was approved by the institutional review board at the Johns Hopkins Medical Institutions.
Pathological assessment of biopsy specimens was performed by expert genitourinary pathologists in accordance with the 2014 International Society of Urological Pathology Consensus Conference (grade group [GG]1 = Gleason score ≤6; GG2 = Gleason score 3 + 4 = 7; GG3 = Gleason score 4 + 3 = 7; GG4 = Gleason score 8; GG5 = Gleason score 9-10) [15] . The primary outcome was clinically significant PCa on biopsy, defined as any Gleason score ≥3 + 4 = 7 (GG2) cancer or Gleason score 3 + 3 = 6 (GG1) cancer detected in >2 cores or >50% of any one core [16, 17] , consistent with the National Comprehensive Cancer Network criteria for low-risk PCa [6] .
Statistical Analysis
Categorical variables were reported as count and proportion; continuous variables were reported as median and interquartile range (IQR). Statistical comparisons were made using the chi-squared or Fisher's exact test for proportions and the Mann-Whitney test for continuous variables, as determined prior to analysis. Univariable logistic regression was performed to determine the association of measured covariates with clinically significant PCa. PHI density was explored as both a continuous variable and categorized across the first quartile (below the 25th percentile value), IQR and fourth quartile (above the 75th percentile value). Model accuracy was assessed by quantifying the area under the receiver-operating characteristic curve (AUC). All comparisons were two-sided and P values <0.05 were taken to indicate statistical significance. Statistical analysis was performed using STATA Intercooled v.14 (College Station, TX, USA).
Results
In total, 318 men meeting the study criteria presented with suspicion of PCa and underwent PHI testing. Of these, 118 (37%) underwent biopsy within 6 months of PHI testing and were included in the study cohort. All biopsied men had a PSA level ≥2.0 ng/mL. Of those not included in the study, 185 did not undergo biopsy and 15 underwent biopsy >6 months from measurement of PHI. Notably, compared with those who did not undergo biopsy, the biopsied cohort included in the study had higher PSA level, PSAD, PHI and PHI density, and lower %fPSA and %fPSA 9 volume (Table S1 ). On biopsy, 47 men (39.8%) were found to have clinically significant PCa. Compared with those with negative biopsy or clinically insignificant PCa, men with clinically significant PCa were more frequently African-American (P = 0.045), had lower %fPSA, prostate volume and %fPSA 9 volume, and had higher PHI, PSAD and PHI density (all P < 0.001; Table 1 ).
Within the study population, PHI density ranged from 0.15 to 4.40, with a median value of 0.70. The 25th and 75th percentile values (lower and upper limits of the IQR) were 0.43 and 1.21, respectively. Among the 47 men found to have clinically significant PCa, 46 (97.9%) had a PHI density >0.43. Based on the threshold of 0.43, PHI density had a sensitivity of 97.9% and specificity of 38.0% for detection of clinically significant disease. PHI density values in the lowest quartile (<0.43) were associated with a negative predictive value of 96.4% for clinically significant PCa. As shown in Fig. 1 , the prevalence of clinically significant PCa increased significantly with increasing categories of PHI density, from 3.6% in men with PHI density <0.43, to 36.7% in men with PHI density 0.43-1.21, and 80.0% in men with PHI density >1.21 (P < 0.001). Notably, the lone patient with PHI density 794 © 2017 The Authors BJU International © 2017 BJU International <0.43 with clinically significant disease was found to have Gleason score 6 cancer in three biopsy cores and <50% cancer involvement in each core; thus representing the lowest pathological risk of disease among clinically significant cancers. As such, PHI density >0.43 conferred 100% sensitivity for Gleason score ≥7 disease (Fig. S1 ).
Univariable logistic regression showed that age was not significantly associated with clinically significant PCa (odds ratio [OR] 1.01, 95% CI 0.96-1.06; P = 0.7), while AfricanAmerican race was associated with more than threefold increased odds, although this association did not reach conventional levels of statistical significance (OR 3.44, 95% CI 0.97-12.16; P = 0.056 [ Table 2 ]). Among the tested diagnostic markers, PSA was not a significant predictor of clinically significant PCa (P = 0.3). By contrast, PSAD (P = 0.001), prostate volume, %fPSA, %fPSA 9 volume, PHI and PHI density (P < 0.001 for each) were each associated with clinically significant PCa. Notably, a 1-unit increase in PHI density was associated with greater than fivefold increased odds of clinically significant PCa (OR 5.64, 95% CI 2.54-12.55; P < 0.001). Compared with men in the lowest quartile of PHI density (<0.43), those with PHI density in the IQR (0.43-1.21) carried >15-fold increased odds of harbouring clinically significant PCa (OR 15.6, 95% CI 1.98-123.1; P = 0.009), and men in the highest quartile (>1.21) had a >100-fold increased odds of clinically significant PCa (OR 108, 95% CI 12.1-962; P < 0.001).
The AUC was used to measure the ability of the diagnostic markers to identify clinically significant disease. The model considering serum PSA alone had poor predictive ability, as demonstrated by an associated AUC of 0.52 (95% CI 0.41-0.63). As shown in (Table S2 ) and in the subpopulation of men (n = 74) with no history of previous biopsy (Table S3) . 
Discussion
Prostate cancer remains the most prevalent non-cutaneous malignancy and second-leading cause of cancer death in Western men [18] . Acknowledging that PCa exists across a wide spectrum of biologies, including many cancers that pose minimal threat to the population, efforts toward screening and early diagnosis are exceedingly controversial [19] . Indeed, a substantial proportion of cancers diagnosed based on serum PSA testing will not prove harmful during a man's lifetime; therefore, the focus of PCa screening has shifted from the traditional aim of identifying all malignancies to the aim of diagnosing only those cancers that are 'clinically significant'; that is, likely to adversely affect a patient during his remaining lifetime [20] . The PHI has been proposed as one tool for advancing this goal. In the present analysis, we sought to assess the accuracy of PHI density for the diagnosis of clinically significant PCa, while exploring potential thresholds for clinical use.
Because previous data suggest that a 25% reduction in biopsies is a feasible and reasonable objective [21] , we initially explored our cohort's 25th percentile value of PHI density (0.43) as a threshold for clinically significant disease. Indeed, we found that PHI density values >0.43 were nearly 98% sensitive for this outcome. Considering the overall distribution of PHI density in the study population, the highest quartile was associated with an 80.0% risk of clinically significant disease, as compared with only 3.6% in the lowest quartile and 36.7% in the IQR. As measured by the AUCs, PHI density (AUC 0.84) offered substantially better discriminatory ability than PSA (0.52), PSAD (0.70), %fPSA (0.75), %fPSA 9 volume (0.79) and PHI (0.76). Importantly, these findings were consistent in a multivariable model considering African-American race, the clinical variable that was most closely associated with this outcome, and in the subgroup of biopsy-na€ ıve men, the population of men consistent with the majority of previous investigations of PHI [11] . Furthermore, these data illustrate the utility of incorporating prostate volume and various PSAderived markers, as those measures considering volume consistently outperformed their corollary measures not accounting for volume.
Across multiple studies, PHI has consistently been shown to have improved diagnostic accuracy for PCa and clinically significant PCa as compared with PSA [9, 13, [22] [23] [24] . This improved accuracy may allow a reduction in the number of men undergoing costly, invasive procedures such as prostate biopsy or mpMRI, while maintaining a very low risk that clinically significant cancers go undetected. For example, Loeb et al. [24] estimated that biopsy could have been avoided in 30.1% of men with no PCa or clinically insignificant PCa if only patients with PHI ≥28.6 were biopsied; that would have amounted to a~23% reduction in overall biopsies in their cohort. The trade-off for this reduction in biopsies was the failure to detect 10.1% of significant cancers, of which 6% were Gleason score ≥7. Our findings using PHI density build on those observed with PHI. Indeed, our data indicate that Despite the utility of other dimension-adjusted indices such as PSAD, PHI density has not been widely explored to this point.
In an Italian population with PSA 2-10 ng/mL referred for prostate biopsy, Mearini et al. [25] observed a relationship between PHI density and the presence of PCa on biopsy that was similar to that which we observed. The median PHI density in their cohort was 0.76, including 0.65 and 1.38 in men without and with PCa on biopsy, respectively. These values are consistent with our cohort, in which we observed median PHI density of 0.70 overall, including 0.53 and 1.21 in men with and without clinically significant PCa. Moreover, they found a PHI density threshold of 0.49 was associated with 90.7% sensitivity and 30.2% specificity for PCa, consistent with our measures of 97.9% and 38.0% for clinically significant PCa. By contrast, the Italian cohort underwent 18-core transperineal biopsy rather than the 12-15 core TRUS-guided biopsy which is standard at our institution. Notably, all men with PSA 2-10 ng/mL referred to their institution underwent diagnostic biopsy and were thus included in the study cohort, while our analysis included only those men who elected to undergo biopsy after consideration of existing clinical data and undergoing shared decision-making. As such, the ability of PHI density to discriminate significant PCa among a cohort already selected for biopsy based on conventional markers is particularly encouraging.
In one other study on PHI density, Ito et al. [26] retrospectively measured PHI density in 239 Japanese men who underwent prostate biopsy between 2004 and 2007. This cohort was similarly limited to men with PSA 2-10 ng/mL, although 18% of the cohort had an abnormal DRE. On biopsy, PCa was detected in 22.2% of patients. Using a PHI density threshold of 0.66, the authors observed a sensitivity of 95% and specificity of 30% for detection of PCa. Again, there are notable differences between this report and ours, including the fact that the present study did not exclude patients with PSA elevated beyond 10.0 ng/mL and therefore may reflect a more 'real-world' cohort. Additionally, the present study was performed in the contemporary clinical setting and may better reflect the current population of men electing to undergo PCa screening. Acknowledging these and other differences, the consistent relationships observed across existing reports are encouraging.
Although promising, these findings must be taken in the context of notable limitations. First, it is necessary to highlight the relatively small sample size of our analysis. As such, the observed ORs include broad CIs. Nonetheless, statistical significance was consistently achieved and the clinical utility of such findings is apparent, particularly in the first and fourth quartile of patients. The limited sample size is largely secondary to the recent introduction of PHI testing to clinical practice at our institution, which confers the contemporary setting of the study -one notable strength. Second, the study population includes only those men who underwent biopsy based on clinical evaluation of standard variables. Those who were not biopsied were probably at lower risk of harbouring PCa, and lack of robust follow-up information on those patients is certainly a limitation in this study. Focusing on biopsied patients only, our findings may not be applicable to the overall population, particularly with regard to potential threshold values. However, the cohort in which biopsy is deemed necessary based on PSA, PSAD, %fPSA and PHI represents the exact population that stands to benefit from the additional information afforded by PHI density. Third, volume-adjusted measures such as PHI density require an accurate determination of prostate volume. The majority of men in the present analysis underwent volume measurement with TRUS at the time of biopsy. Certainly, TRUS without biopsy could be initially performed to obtain prostate volume with minimal morbidity. Alternatively, mpMRI has been widely adopted in the diagnostic setting and offers excellent concordance with ultrasonographyderived volume [27] . Fourth, the present analysis did not consider other emerging diagnostic tools, such as mpMRI or candidate urinary biomarkers, which may have influenced the decision-making process leading to biopsy, thereby influencing the study cohort. Finally, the present study included only a small number of clinical and demographic factors for multivariable modelling. Future studies using more comprehensive data may achieve superior diagnostic performance through the use of multivariable nomograms incorporating PHI density. Acknowledging these and other limitations, PHI density appears to be a simple, useful tool to aid in diagnosing clinically significant PCa. Further evaluation in larger populations is necessary to better characterize the potential utility.
In conclusion, in a contemporary population of men undergoing diagnostic evaluation for prostate cancer, PHI density is a relatively simple measure which appears to be superior to PSA and other PSA derivatives for the identification of clinically significant disease. In our experience, use of PHI density could have avoided 38% of unnecessary biopsies at a cost of failing to detect only 2% of clinically significant cancers. Additional study is necessary to further explore the potential utility of this diagnostic tool.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1 PHI density values by biopsy grade group. Table S1 Characteristics of the biopsied and non-biopsied cohorts. Table S2 Multivariable logistic regression models including African-American race. Table S3 Univariable logistic regression models and corresponding AUCs for the prediction of clinicallysignificant PCa in the subgroup of men without a previous biopsy (n = 74).
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